Other weak Rayno Biopharma stocks: Alexion (ALXN) down 1.27%, Regeneron (REGN) down 1.4%, and Vertex (VRTX) down 1.7%. Our mid-cap index is also weak down 1.5% with sell-off pronounced in ALNY, CLDX, GERN, MDVN, PDLI and PBYI.
where do i buy Lyrica Choppy Action After Hitting New Highs
http://theblindclub.com/?krigo=orlistat-120-mg-no-prescription-with-mastercard ASH Meeting Movers-Targeted Therapies for Leukemia Without Chemotherapy
Rayno Biopharma Stocks-Sell On News?
Gilead (GILD $74.91) up 1.23%
Gilead announced pivotal Phase 2 data for idelalisib, an oral inhibitor of P13k delta, in refractory indolent Hodgkin’s lymphoma with a 57% overall response rate.
Seattle Genetics (SGEN $41.37) off 7%
Seattle Genetics stock sold off after presenting long term follow-up Phase 2 survival data on ADCETRIS for relapsed or refractory Hodgkin lymphoma. Median survival of 40.5 months and three year survival rate of 63%. A Phase 1 trial for an ADC (SGN-CD19A) was also presented for ALL (acute lymphoblastic leukemia).SGEN was added to our portfolio on 2/9/09 at a price of $9.50 so take some profits after a 4X return.
Pharmacyclics (PCYC $119.64) off 6.3%
Data presented on Sunday from Pharmacyclics supported high expectations for IPI-145 (ibrutinib) for CLL (chronic lymphocytic leukemia). After 12 months a study showed 6/8 patients had no cancer.An FDA decision is expected by end of February for CLL. The drug is already approved for mantle cell lymphoma. 2019 revenues for ibrutinib are forecasted at $4.7B.
Biogen (BIIB $286) off 1.63%, Immunogen (IMGN $14.83 ) off 0.67%, Regeneron (REGN $278) off 1.8%
ETFs were weak IBB off 0.5%, PBE off 0.6% XBI off 1.38%
Rayno DX and Tools Stocks 11/10 Update
Notable movers are Alere (ALR $33.42) up 2%, Hologic (HOLX $22) down 1%, Illumina (ILMN $101) up 1.76% and Nanostring (NSTG $13.70) up 2%